The Annals Visit the NEW pharmaCE.com
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 7 June 2005, www.theannals.com, DOI 10.1345/aph.1E069.
This Article
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moreland, A. J
Right arrow Articles by Makela, E. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moreland, A. J
Right arrow Articles by Makela, E. H


ARTICLES

Selective Serotonin-Reuptake Inhibitors in the Treatment of Premature Ejaculation (CE) (July/August)

Amanda J Moreland 1 Eugene H Makela PharmD BCPP2*

1 PharmD Student, School of Pharmacy, West Virginia University, Morgantown, WV
2 Associate Professor, Department of Clinical Pharmacy, Schools of Pharmacy and Medicine, West Virginia University

* To whom correspondence should be addressed. E-mail: gmakela{at}hsc.wvu.edu.


   Abstract

OBJECTIVE: To review the use of selective serotonin-reuptake inhibitors (SSRIs) in the treatment of premature ejaculation.

DATA SOURCES: Articles were retrieved through a MEDLINE search (1966-January 2004). Search terms used to identify articles included serotonin uptake inhibitors, premature ejaculation, rapid ejaculation, and sexual behavior, as well as the generic names of currently available SSRIs: fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram. The literature search was limited to articles published in the English language containing human subjects.

STUDY SELECTION AND DATA EXTRACTION: Articles obtained through the literature search were evaluated, and randomized controlled trials were included in this review. Information from noncontrolled trials or case reports was considered for inclusion if it contributed to the completeness of this review and if it was the highest level of evidence available.

DATA SYNTHESIS: Premature ejaculation is a commonly reported sexual difficulty. Delayed ejaculation is a widely reported sexual adverse effect of SSRIs. In some men exhibiting premature ejaculation, the ability of the SSRIs to delay ejaculation has been therapeutic. Trials evaluating the ejaculation-delaying ability of SSRIs demonstrated that paroxetine, fluoxetine, sertraline, and citalopram produce a statistically significant increase in the ejaculation latency time compared with placebo.

CONCLUSIONS: Taking advantage of the ejaculation-delaying effects of SSRIs increases the treatment options available to prescribers and patients. Convenience and minimal adverse effect profile make these agents an alternative to previously used behavior modalities and older pharmacologic agents. Although some questions still surround the details of their use, SSRIs have the potential to improve the quality of life for men with premature ejaculation and their partners.

(CE) This article is approved for continuing education credit

ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-xxx-H01

Key Words: selective serotonin-reuptake inhibitors: citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, premature ejaculation.

Reprints: Dr. Makela, Schools of Pharmacy and Medicine, PO Box 9520, West Virginia University, Morgantown, WV 26506-9520, fax 304/293-7672, gmakela@hsc.wvu.edu







homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.